




# Veterinary medicinal products: authorisations and drug safety 2023

## Contents


<b>1</b>	<b>Authorised veterinary medicinal products (2021 to 2023)</b>	<b>3</b>
<b>2</b>	<b>Distribution by target animal species 2023</b>	<b>3</b>
<b>3</b>	<b>Completed authorisation procedures (2021 to 2023)</b>	<b>4</b>
<b>4</b>	<b>Distribution by ATCvet 2023</b>	<b>5</b>
<b>5</b>	<b>Newly authorised veterinary medicinal products 2023</b>	<b>6</b>
<b>6</b>	<b>Drug safety for veterinary medicinal products 2023</b>	<b>7</b>
<b>7</b>	<b>Number of reports of adverse veterinary drug reactions (2021 to 2023)</b>	<b>8</b>

## 1 Authorised veterinary medicinal products (2021 to 2023)<sup>1</sup>



## 2 Distribution by target animal species 2023

On average, one veterinary medicinal product (VMP) was authorised for just under two target animal species, i.e. in target species terms, there were approximately 1,400 authorisations (previous year: 1,300). The addition of immunological veterinary medicinal products had a significant impact on the distribution of authorisations for the commonest target species only in absolute terms. The percentage distribution remains almost unchanged:




Source of animal pictograms: Page 7

<sup>1</sup> From 2023 including immunological veterinary medicinal products

In terms of the target species specifically mentioned in the chart, there were 537 authorisations for pets (dogs, cats and «pet» horses) and 693 for livestock (cattle, pigs, «working» horses, sheep and goats) as at the end of 2023. The 148 authorisations for horses break down into 136 for «working» horses and 12 for «pet» horses.

The «Other» category includes the following species in descending order: «Pets excluding ornamental fish» (25 authorisations), poultry (21; previous year 11), «livestock» (18), ruminants (17), «animals» (13), rabbits (12), chickens (12), ornamental fish (11; previous year 21), exotics (10), ferrets (9), bees (8), guinea pigs (5), exotic birds (5), small rodents (4), donkeys (4), zoo and wild animals (2), turkeys (2), fish (1), broiler chickens (1), broiler turkeys (1), boars (1), foxes (1), pigeons/doves (1).

### 3 Completed authorisation procedures (2021 to 2023)



Between 2021 and 2023, around half of veterinary medicinal products with known active substances with and without innovation were authorised under Art. 13 TPA<sup>2</sup>, while one veterinary medicinal product with a new active substance and four veterinary medicinal products with known active substances with or without innovation were authorised under Art. 14 para. 1 let. a<sup>bis</sup>.

<sup>2</sup>Therapeutic Products Act (SR 812 21)

## 4 Distribution by ATCvet 2023

The vast majority of authorised veterinary medicinal products were in groups QP: antiparasitic products (19%), QJ: anti-infectives (18%) and QI: immunologicals (15%). The other major groups are QM: musculoskeletal system (9%), QN: nervous system (7%), QA: alimentary tract and metabolism (6%) and QG: genito-urinary system and sex hormones (5%).

The remaining eight ATCvet groups account for less than 5% each and together represent just under 20% of all authorised VMPs. The smallest group – QL: antineoplastic and immunomodulating veterinary medicinal products – accounts for just 1.3% of all authorised veterinary medicinal products.

Source of animal pictograms: Quality review of documents (QRD) guidance on the use of approved pictograms on the packaging of veterinary medicinal products authorised via the centralised (CP), mutual recognition (MRP) and decentralised procedures (DCP), available at: <https://www.ema.europa.eu/en/qrd-guidance-use-approved-pictograms-packaging-veterinary-medicinal-products-authorized-centralised-mutual-recognition-decentralised-procedures-species-pictograms>. Colour has been changed from black (original) to grey.

## 5 Newly authorised veterinary medicinal products 2023

19 new veterinary medicinal products (including four vaccines) were authorised during 2023: 13 for pets (six for dogs, five for cats, one for dogs and cats and one for cats and ferrets) and six for livestock (two each for horses and cattle, one for pigs and one for lambs and calves). The individual authorised veterinary medicinal products were:

Authorisation number	Name	Indication
68816	Cortotic 0.584 mg/ml ad us. vet., ear spray for dogs	Ear spray for dogs for the treatment of otitis externa
68874	Eluracat 20 mg/ml ad us. vet., oral solution for cats	For weight gain in cats with inappetence or unintended weight loss due to chronic kidney disease
68891	Dycoxon 2.5 mg/ml ad us. vet., oral suspension for lambs and calves	Anticoccidial for lambs and calves
68904	Canishield ad us. vet., medicated collar for dogs	Antiparasitic against flea and tick infestation, for the prevention of leishmaniasis and for the prevention of Culex mosquito bites
68918	Combotec Spot-On for Cats and Ferrets ad us. vet., spot-on solution	Insecticidal and acaricidal solution for topical application to the skin, for cats and ferrets
68919	Combotec Spot-On for Dogs ad us. vet., spot-on solution	Insecticidal and acaricidal solution for topical application to the skin, for dogs
68958	Senvelgo 15 mg/ml ad us. vet., oral solution for cats	Treatment of diabetes mellitus in cats
68985	Felpreva ad us. vet., spot-on solution for cats	For cats with, or at risk from, mixed parasitic infestations/infections
69002	Pergosafe ad us. vet., film-coated tablets for horses	Dopamine agonist for horses
69018	Enrocat flavour 25 mg/ml ad us. vet., oral suspension for cats	Antibiotic (gyrase inhibitor) for cats
69097	Twinox ad us. vet., chewable tablets for cats and dogs	Antibiotic for cats and dogs
69133	Daxocox ad us. vet., flavoured tablets for dogs	For the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs.
69179	Thiamacare 10 mg/ml ad us. vet., oral solution for cats	For the long-term treatment and stabilisation of hyperthyroidism in cats prior to surgical thyroidectomy. For the stabilisation of hyperthyroidism in cats prior to surgical thyroidectomy or radioiodine therapy.
69224	Ficoxil ad us. vet., chewable tablets for dogs	Non-steroidal anti-inflammatory drug for dogs

Authorisation number	Name	Indication
69278	Equilis West Nile ad us. vet., suspension for injection for horses	Inactivated vaccine against the West Nile virus in horses
69279	Rispoval 2 / BRSV + Pi3 ad us. vet., lyophilisate and solvent for suspension for injection for cattle	Attenuated live vaccine against bovine respiratory syncytial virus and bovine parainfluenza virus in cattle
69281	Fencovis ad us. vet., suspension for injection for cattle	Inactivated viral and bacterial vaccine against rotavirus, coronavirus and E. coli in cattle
69282	CircoMax ad us. vet., emulsion for injection for pigs	Inactivated, recombinant vaccine against porcine circovirus in pigs
69357	Cardisan ad us. vet., chewable tablets for dogs	Cardiovascular therapeutic for dogs


## 6 Drug safety for veterinary medicinal products 2023

### A summary of the main points

- 462 reports: 391 involving small animals/pets (incl. exotics) (including 273 dogs and 115 cats), 71 involving livestock (including 41 cows/cattle/calves and 14 horses), one reaction in a user
- Most frequent medicinal product types: antiparasitics (142), immunological veterinary medicinal products (111), hormone products (82) products to modulate the nervous system (38), anti-infectives (12)
- 125 cases of suspected lack of efficacy, largely for antiparasitics and hormone products
- 54 cases forwarded by Tox Info Suisse, including 30 cases of accidental ingestion of flavoured tablets by dogs or cats
- 113 cases of human exposure to veterinary medicinal products, most frequently antiparasitic products. 33 cases of confusion with human medicinal products, 32 cases of exposure in young children and 31 cases of skin contact, primarily with solutions.

15 signals opened, eight closed. Examples: Hypersensitivity reactions after the use of various immunological veterinary medicinal products, neurological symptoms after the use of a flea collar for dogs, potential risk for female users and pregnant animals when using veterinary medicinal products containing the excipient N-methyl-pyrrolidone.

## 7 Number of reports of adverse veterinary drug reactions (2021 to 2023)<sup>3</sup>



<sup>3</sup> From 2023 including immunological veterinary medicinal products



## Credits

### **Publisher**

Swissmedic, Swiss Agency for Therapeutic Products  
Medicinal Product Authorisation and Vigilance Sector  
Veterinary Medicines Division  
Hallerstrasse 7  
3012 Bern  
Switzerland  
[www.swissmedic.ch](http://www.swissmedic.ch)

### **Editors/contacts**

Cedric Müntener, Veterinary Assessor  
Peter Schmid, Regulatory Manager

### **Layout and typesetting**

Swissmedic, Communication Division



Schweizerisches Heilmittelinstitut  
Institut suisse des produits thérapeutiques  
Istituto svizzero per gli agenti terapeutici  
Swiss Agency for Therapeutic Products

Swissmedic, Swiss Agency for Therapeutic Products  
Medicinal Product Authorisation and Vigilance Sector  
Veterinary Medicines Division  
Hallerstrasse 7  
3012 Bern  
Switzerland  
[www.swissmedic.ch](http://www.swissmedic.ch)

